TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04026581

Intervention type: BEHAVIORAL
Intervention: Speech generating device (SGD) evaluation including BCI access
Description: At the initial evaluation the participants will review the full range of AAC options and speech generating devices (SGDs) and complete a speech and language evaluation. The second evaluation date will involve a trial of SGDs matched to the participant's assessment results. The third visit is the trial of an AAC system with BCI access. Should the dry electrode headgear for BCI access prove ineffective, then the gel electrode cap will be offered to the participant for trial. At the end of the third visit, the evaluation results will be discussed with participant and family, and they will be asked to select the preferred SGD.
Study: NCT04026581

Intervention type: BEHAVIORAL
Intervention: Training and treatment
Description: Participants receive training on the selected SGD followed by monthly treatment sessions from the SLP who monitors performance. In some cases the participants' SGD will be an AAC system with BCI access. In this case training will also include an identified system support person. Use of the SGD is monitored on a monthly basis through home visits and/or tele-practice sessions, when requested. Technical support for the SGD is provided on an as needed basis or when requested by the participant or support person.
Study: NCT02474680

Intervention type: GENETIC
Intervention: Pharmacogenetic testing
Description: Psychotropic genotyping panel
Study: NCT04224883

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuously feeding
Description: Daily amount of feeding were continuously pumped for 24 hours. EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours. If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200mL were considered markers of good tolerance.Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 16-hours feeding
Description: Daily amount of feeding were continuously pumped for 16 hours.EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intermittent feeding
Description: Daily amount of feeding were divided into four meals, each meal are pumped within 60mins or 120mins through stomach tube. EN preparation pumping scheme was as follows: If the volume of each meal is less than or equal to 250ml(≤250ml), pump in within 60min, if volume is greater than 250ml(\>250ml), pump in within 120min and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
Study: NCT01703286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching Glimepiride
Study: NCT01703286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: given once daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching Linagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Linagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Glimepiride
Study: NCT04766372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behaviour change
Description: Using needs supportive, self-determination theory-based, components to improve the physical activity behaviours of adolescent girls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behaviour change
Description: Using needs supportive, self-determination theory-based, components to improve the physical activity behaviours of adolescent girls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behaviour change
Description: Using needs supportive, self-determination theory-based, components to improve the physical activity behaviours of adolescent girls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behaviour change
Description: Using needs supportive, self-determination theory-based, components to improve the physical activity behaviours of adolescent girls.
Study: NCT03977454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve Block
Description: Nerve blocks (QLB/LFCNB) to be placed preoperatively with DEX/MPA, per standard of care of anesthesia block service.~1. QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA~2. LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular Injection (PAI)
Description: Intraoperatively, the surgeon will perform PAI per standard of care with the medications:~1. 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 60 ml 0.2% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 60 ml 0.2% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dex
Description: 10 mg DEX/ 80 mg MPA
Study: NCT00963677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasotracheal Intubation through seeing optical stylet (SOS)
Description: Nasotracheal intubation using seeing optical stylet in the patients with the anticipated difficult intubation. Arm 1:routine anesthesia induction,0.1mg/kg midazolam, 3-8mcg/kg fentanyl, 0.08-0.15mg/kg vecuronium and 0.3mg/kg etomidate, Nasotracheal intubation with seeing optical shikani; Arms 2: Sevoflurane combined with oxyge, 0.3mg/kg Etomidate and 1-2mg/kg succinylcholine for intubation, nasotracheal intubation with seeing optical shikani

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasotracheal Intubation through seeing optical stylet (SOS)
Description: Nasotracheal intubation using seeing optical stylet in the patients with the anticipated difficult intubation. Arm 1:routine anesthesia induction,0.1mg/kg midazolam, 3-8mcg/kg fentanyl, 0.08-0.15mg/kg vecuronium and 0.3mg/kg etomidate, Nasotracheal intubation with seeing optical shikani; Arms 2: Sevoflurane combined with oxyge, 0.3mg/kg Etomidate and 1-2mg/kg succinylcholine for intubation, nasotracheal intubation with seeing optical shikani
Study: NCT01159977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated small groups
Description: 1 hour sessions every 2 weeks for small groups of 9 participants, 19 sessions over 9 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured time.
Description: 1 protected hour every 2 weeks for 9 months, without small group structure.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual practice
Description: No protected time provided.
Study: NCT04637906

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bioarginina®
Description: Food supplement based on 1,66 grams of L-arginine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bioarginina®
Description: Food supplement based on 1,66 grams of L-arginine
Study: NCT01703286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
Study: NCT03580577

Intervention type: DEVICE
Intervention: thromboelastography
Description: thromboelastography will assess all coagulation abnormalities including platelets function in cirrhotic group with venous thromboembolism , and guide us about is there increased thrombosis risk or not, for that a fresh blood sample will be withdrawn from each patient before starting any treatment
Study: NCT00540722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-gossypol acetic acid
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00755352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin tablets and Welchol tablets
Description: pravastatin tablets, 1 tablet/day for 6 weeks; Welchol Tablets, 6 tablets/day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pravastatin tablets and Welchol placebo tablets
Description: pravastatin tablets, 1 tablet/day; Welchol placebo tablets, 6 tablets/day
Study: NCT01875003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at high or low dose Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at high or low dose Q4W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at high or low dose Q4W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lebrikizumab matching placebo will be administered as SC injection Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists \[LABAs\], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists \[LABAs\], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists \[LABAs\], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
Study: NCT03793218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Latera Device
Description: This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alar Batten Graft
Description: This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant
Study: NCT02886156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP plus BSC group Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center. Participants in both groups will be asked to continue their usual medical care during the trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BSC
Description: BSC only group Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BSC
Description: BSC only group Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
Study: NCT00715169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLN1202
Description: 10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consist of 0.9% saline solution administered as a 10 mg/kg dose via IV infusion administered approximately 30 minutes to an hour
Study: NCT01218282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise training
Description: 20-30 min/day for at least 4 days/week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise training
Description: 20-30 min/day for at least 4 days/week

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: NO Exercise Training
Description: No intervention
Study: NCT02861131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg through an intravenous line with brisk flow

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be administered with Neostigmine at a dose between 0.1 to 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered.
Study: NCT01684020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARTISS human fibrin sealant
Study: NCT04176887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam Injection
Description: The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
Study: NCT03818997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: Patient will receive DKN-01 300 mg IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: Patient will receive DKN-01 300 mg IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Patient will receive Atezolizumab 840 mg IV every 2 weeks until PD
Study: NCT02402192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corifollitropin alfa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corifollitropin alfa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corifollitropin alfa
Study: NCT02983903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transbronchial biopsy
Study: NCT02456116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture/PCA/NSAID
Description: standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture/PCA/NSAID
Description: standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5
Study: NCT04176887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin Injection
Description: Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
Study: NCT00562744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation
Description: Use of high-fidelity patient simulator for training and assessment of PALS scenario performance
Study: NCT01244698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil discontinued early
Description: All patients will receive 24 hours of IV Cefazolin (1g IV every 8 hr), as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics. Clindamycin IV 600mg every 6 hours for 24 hours will be used in penicillin allergic patients.

Intervention type: DRUG
Group type: OTHER
Intervention: Cefadroxil until drain removal
Description: All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil (500mg 2 times a day) until the final drain is removed. This is the normal postoperative regimen. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin 600mg IV every 6 hours for 24 hours followed by clindamycin 300mg IV every 6 hours.
Study: NCT02309866

Intervention type: GENETIC
Intervention: Genetic testing
Description: Genetic testing for mutations in known and novel genes underlying RP and allied diseases
Study: NCT03918681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Intervention
Description: Instruction for all participants in the experimental group will begin with transitioning foot strike pattern from a rearfoot strike to a non-rearfoot strike running pattern (NRFS) and increasing preferred step rate by 5-10%. Each participant program thereafter will be progressed individually according to the clinical investigators follow up assessments of running mechanics and participant pain and function with running. Intervention gait retraining sessions will include drills for reinforcement to include soft landing single leg bounding, adequate time to practice, and pre-class and post-class video assessment with feedback.
Study: NCT04437953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Patients will receive an initial dose of Avatrombopag 60 mg on Day 1. Starting on Day 2, the dose will be Avatrombopag 20 mg daily. Once a patient has reached a platelet target of \> 100,000/mcL patients can initiate systemic cancer therapy. Avatrombopag will be continued as maintenance (subscript m) and titrated weekly with a goal to maintain a platelet count of ≥ 100,000/mcL during administration of systemic cancer therapy. Duration of maintenance therapy will be at least 12 weeks (indicated by Week 1m, Week 2m, ... 12m) starting from time of platelet correction and resumption of systemic cancer therapy. End of Treatment (EOT) is up to 15 weeks on study Week 12m.
Study: NCT00630474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xylometazoline
Description: xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: xylometazoline
Description: xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
Study: NCT03210987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient case presentation bedside
Description: Patient case presentation in absence or presence of Patient at bedside.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient case presentation Outside-the-room
Description: Patient case presentation Outside-the-room.
Study: NCT01519154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Only Propofol titrated for induction, followed by Propofol 10 mg/h as maintenance infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine-Propofol
Description: Propofol titrated plus additional Ketamine 1 mg/kg at induction, followed by Propofol 10 mg/h as maintenance infusion
Study: NCT06400979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elequil aromatab
Description: Aromatherapy impregnated tab utilized to dispense inhaled scent for the study
Study: NCT04537260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: Those in the intervention arm were asked to watch the 3-minute educational video prior to the knowledge questionnaire and meeting their provider (midwife or obstetrician). The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8.
Study: NCT01236014

Intervention type: DRUG
Intervention: Eltrombopag
Description: Eltrombopag \& standard of care

Intervention type: DRUG
Intervention: Romiplostim
Description: Romiplostim \& standard of care
Study: NCT02489045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE measurement (Sonazoid ultrasoud contrast agent)
Description: Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
Study: NCT03324412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of MTX
Description: Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg， 3 times a day, oral, for 24 weeks.
Study: NCT01236014

Intervention type: DRUG
Intervention: Placebo
Description: Placebo \& standard of care
Study: NCT02670174

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Separate kinetic chain training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated kinetic chain training
Study: NCT03925168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy will be administered according to the Eyre (2008) decision tree model. According to this model, the patient chooses his or her preferred musical intervention at the beginning of each session. Choices include: sing songs, compose a song, listen to songs, play instruments, have an imagery experience, listen to music, improvise, and use music for relaxation.
Study: NCT02487823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide
Description: BKM 120, LH-RH agonists and Bicalutamide
Study: NCT03324412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of MTX and TwHF
Description: Methotrexate : 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）：20mg， 3 times a day, oral, for 24 weeks.
Study: NCT03940157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oh Happy Day Class - Still I Rise
Description: one-time, 4-hour class focused on awareness of depression and healthy self-management strategies